Management of Chronic Insomnia with Low Dependence Risk

First‑Line Non‑Pharmacologic Therapy

• Cognitive‑behavioral therapy for insomnia (CBT‑I) is more effective than any medication for chronic insomnia, providing superior long‑term outcomes without risk of dependence, tolerance, or withdrawal. (high‑quality evidence) 3
• CBT‑I yields short‑term (2–4 weeks) improvements comparable to pharmacologic agents, but its efficacy continues to exceed medication effects beyond this period. (moderate‑quality evidence) 3
• Transient sleepiness that can occur during the initial sleep‑restriction component of CBT‑I resolves quickly as therapy progresses. (moderate‑quality evidence) 1

Preferred Pharmacologic Options When CBT‑I Is Unavailable or Declined

Low‑Dose Doxepin (3–6 mg)

• Improves sleep latency, total sleep time, and overall sleep quality in both older and younger adults. (moderate‑quality evidence) 1, 2
• Adverse‑event rates are not statistically different from placebo in clinical trials. (high‑quality evidence) 1, 4
• No black‑box warning for suicide risk, although a residual risk cannot be completely excluded. (moderate‑quality evidence) 2, 5
• Should be prescribed at the lowest effective dose for the shortest necessary duration. (expert consensus) 1

Orexin Receptor Antagonists (Suvorexant, Lemborexant, Daridorexant)

• These agents are recommended as first‑line pharmacologic options because they have minimal dependence risk and are effective for sleep maintenance. (guideline consensus) 1, 2

Medications to Avoid Because of Dependence or Safety Concerns

Benzodiazepines

• High risk of dependency and diversion. (moderate‑quality evidence) 1, 6
• Associated with falls and cognitive impairment, particularly in older adults. (moderate‑quality evidence) 1, 6
• Can cause hypoventilation in patients with underlying respiratory disorders such as sleep apnea or obesity‑hypoventilation syndrome. (moderate‑quality evidence) 1
• Harms substantially outweigh any sleep‑benefit despite demonstrated efficacy for sleep parameters. (moderate‑quality evidence) 1, 3

Z‑Drugs (Zolpidem, Zaleplon, Eszopiclone)

• FDA safety warning for serious injuries (e.g., sleepwalking, sleep‑driving) that occur while patients are not fully awake. (high‑quality evidence) 1, 5
• If use is unavoidable, prescribe the lowest effective dose for the shortest duration and provide counseling on parasomnia and safety risks. (expert consensus) 1, 4

Trazodone

• No improvement in sleep efficiency compared with placebo. (moderate‑quality evidence) 1, 6
• Evidence quality is low; adverse‑effect profile outweighs limited sleep benefits. (low‑quality evidence) 1, 2
• Fails to improve sleep‑onset latency, total sleep time, or wake after sleep onset. (moderate‑quality evidence) 3

Antihistamines (e.g., Diphenhydramine)

• 2019 Beers Criteria strongly recommend avoiding these agents in older adults due to antimuscarinic effects. (high‑quality guideline) 2, 5
• Rapid tolerance develops after 3–4 days of continuous use, limiting any short‑term benefit. (moderate‑quality evidence) 2, 7

Antipsychotics (e.g., Quetiapine)

• Evidence is sparse and unclear, based on small sample sizes. (low‑quality evidence) 2, 5
• Increased risk of death in elderly patients with dementia‑related psychosis. (high‑quality evidence) 5
• Associated with heightened suicidal tendencies in children, adolescents, and young adults. (high‑quality evidence) 5

Herbal Supplements

• Kava carries an FDA warning for acute liver injury and death; strong recommendation against its use. (high‑quality regulatory warning) 6, 7
• Valerian and chamomile show no benefit for sleep outcomes in systematic reviews. (moderate‑quality evidence) 6, 7

Critical Pitfalls and Safety Considerations

• Never use benzodiazepines as first‑line therapy for chronic insomnia; the dependency risk is unacceptable. (expert consensus) 1, 6
• Avoid antihistamines in older adults because of anticholinergic burden and rapid tolerance development. (expert consensus) 2, 5
• Do not prescribe Z‑drugs without extensive counseling on the risk of complex sleep‑related behaviors. (expert consensus) 1, 5
• Long‑term adverse effects of most insomnia medications remain unclear; therefore, limit use to the shortest effective duration. (moderate‑quality evidence) 8